v3.21.1
Consolidated Statements of Loss and Comprehensive Loss - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Consolidated Statements of Loss and Comprehensive Loss    
Revenues, net of discounts $ 155,114,454 $ 75,195,556
Cost of goods sold before biological asset adjustments 66,555,710 37,009,909
Incremental costs to acquire cannabis inventory in a business combination [Note 4]   3,764,678
Cost of goods sold 66,555,710 40,774,587
Gross profit before fair value adjustments 88,558,744 34,420,969
Fair value adjustment on sale of inventory (34,147,938) (18,272,212)
Unrealized gain on biological asset transformation [Note 6] 48,690,657 10,108,105
Gross profit 103,101,463 26,256,862
Expenses    
General and administrative [Note 16] 36,342,955 19,036,452
Sales and marketing 2,150,536 1,345,009
Depreciation [Notes 7 and 9] 2,364,224 1,392,994
Amortization [Note 8] 12,024,715 7,222,595
Stock-based compensation [Note 17] 31,156,759 28,879,225
Acquisition expense 2,945,194 5,847,800
Total expenses 86,984,383 63,724,075
Income (Loss) from operations 16,117,080 (37,467,213)
Share of loss on equity investments [Note 10] (33,591) (72,600)
Foreign exchange (7,782) (141,106)
Fair value loss on financial liabilities [Note 14] (164,042,264) (119,235,147)
Interest expense (4,115,775) (3,035,492)
Interest income 10,112 404,835
Other 104,931 202,610
Total other (expense) income (168,084,369) (121,876,900)
Loss before income tax (151,967,289) (159,344,113)
Current tax [Note 20] (21,976,761) (8,728,061)
Deferred tax [Note 20] (2,388,608) 3,892,570
Net loss (176,332,658) (164,179,604)
Foreign currency translation adjustment (9,030,828) (156,510)
Net loss and comprehensive loss $ (185,363,486) $ (164,336,114)
Basic and diluted loss per share $ (6.32) $ (9.43)
Weighted average number of shares outstanding (basic and diluted) 27,892,441 17,404,742